The collaborators have signed a two-year research and license option agreement to develop novel T-cell therapies for cancer using genome editing technology.
The firm is developing products suited for pharmaceutical development from biomarker discovery through companion diagnostics and disease monitoring.
The data included results from thousands of clinically tested samples showing frequent identification of clinically useful diagnostic and prognostic markers.
The company is focusing on hematological malignancies and looking to partner with pharmaceutical companies for companion diagnostics.
Despite an initial focus on cardiovascular disease, Miragen has moved programs in hematological cancer and fibrosis to the front of its pipeline.
The partners will map genomic variation and study its effects on patient outcomes to provide a resource for the prognosis of cancer patients and to help guide treatment for them.
The deal covers tests based on bone marrow and peripheral blood for hematologic cancers.
One of four new research centers, the collaborative network will look to push genomic and cell therapy technologies into clinical trials.
The researchers discovered mutations in essentially the same genes and came to very similar conclusions with regard to the increased cancer risk.
NEW YORK (GenomeWeb) – NeoGenomics today reported a 37 percent year-over-year increase in its third quarter revenues.
CNN reports that researchers have tied a new variant to opioid addiction risk.
Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.
An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.
In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.